Study of APTO-253 in Patients with Relapsed or Refractory Acute Myelogenous Leukemia or High-Risk Myelodysplasia
This is a phase 1b study to determine the maximum tolerated dose (MTD), dose limiting toxicity (DLT) and recommended phase 2 dose of APTO-253 HCl in patients with relapsed or refractory hematologic malignancies.
Study phase: I
Basic eligibility criteria:
Please contact the study coordinator for additional eligibility information.
Age: 18 years of age or older
Gender: Male or female
Diagnosis: Histologically or cytologically proven diagnosis of hematologic malignancies for whom all standard therapy options have failed. Meet laboratory parameter requirements at study entry
Primary disease category: Cancer
Sponsor: Aptose Biosciences, Inc.
Projected enrollment dates: April 2017 to December 2017
Official study title: A Phase Ib Dose Escalation and Expansion, Multicenter, Open-label, Safety, Pharmacokinetic and Pharmacodynamic Study of APTO-253 in Patients with Relapsed or Refractory Acute Myelogenous Leukemia or High-Risk Myelodysplasia
ClinicalTrials.gov page:
http://www.clinicaltrials.gov/show/NCT02267863